Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

Dick De Zeeuw, Tadao Akizawa, Paul Audhya, George L. Bakris, Melanie Chin, Heidi Christ-Schmidt, Angie Goldsberry, Mark Houser, Melissa Krauth, Hiddo J. Lambers Heerspink, John J. McMurray, Colin J. Meyer, Hans Henrik Parving, Giuseppe Remuzzi, Robert D. Toto, Nosratola D. Vaziri, Christoph Wanner, Janet Wittes, Danielle Wrolstad, Glenn M. Chertow

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to

Original languageEnglish
Pages (from-to)2492-2503
Number of pages12
JournalNew England Journal of Medicine
Volume369
Issue number26
DOIs
Publication statusPublished - 2013

Fingerprint

Chronic Renal Insufficiency
Type 2 Diabetes Mellitus
GATA1 Transcription Factor
Diabetic Nephropathies
Renin-Angiotensin System
Glomerular Filtration Rate
methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

De Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., ... Chertow, G. M. (2013). Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New England Journal of Medicine, 369(26), 2492-2503. https://doi.org/10.1056/NEJMoa1306033

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. / De Zeeuw, Dick; Akizawa, Tadao; Audhya, Paul; Bakris, George L.; Chin, Melanie; Christ-Schmidt, Heidi; Goldsberry, Angie; Houser, Mark; Krauth, Melissa; Lambers Heerspink, Hiddo J.; McMurray, John J.; Meyer, Colin J.; Parving, Hans Henrik; Remuzzi, Giuseppe; Toto, Robert D.; Vaziri, Nosratola D.; Wanner, Christoph; Wittes, Janet; Wrolstad, Danielle; Chertow, Glenn M.

In: New England Journal of Medicine, Vol. 369, No. 26, 2013, p. 2492-2503.

Research output: Contribution to journalArticle

De Zeeuw, D, Akizawa, T, Audhya, P, Bakris, GL, Chin, M, Christ-Schmidt, H, Goldsberry, A, Houser, M, Krauth, M, Lambers Heerspink, HJ, McMurray, JJ, Meyer, CJ, Parving, HH, Remuzzi, G, Toto, RD, Vaziri, ND, Wanner, C, Wittes, J, Wrolstad, D & Chertow, GM 2013, 'Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease', New England Journal of Medicine, vol. 369, no. 26, pp. 2492-2503. https://doi.org/10.1056/NEJMoa1306033
De Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. New England Journal of Medicine. 2013;369(26):2492-2503. https://doi.org/10.1056/NEJMoa1306033
De Zeeuw, Dick ; Akizawa, Tadao ; Audhya, Paul ; Bakris, George L. ; Chin, Melanie ; Christ-Schmidt, Heidi ; Goldsberry, Angie ; Houser, Mark ; Krauth, Melissa ; Lambers Heerspink, Hiddo J. ; McMurray, John J. ; Meyer, Colin J. ; Parving, Hans Henrik ; Remuzzi, Giuseppe ; Toto, Robert D. ; Vaziri, Nosratola D. ; Wanner, Christoph ; Wittes, Janet ; Wrolstad, Danielle ; Chertow, Glenn M. / Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. In: New England Journal of Medicine. 2013 ; Vol. 369, No. 26. pp. 2492-2503.
@article{10b9f87050034fae8c8aebe8ad6326d6,
title = "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease",
abstract = "BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to",
author = "{De Zeeuw}, Dick and Tadao Akizawa and Paul Audhya and Bakris, {George L.} and Melanie Chin and Heidi Christ-Schmidt and Angie Goldsberry and Mark Houser and Melissa Krauth and {Lambers Heerspink}, {Hiddo J.} and McMurray, {John J.} and Meyer, {Colin J.} and Parving, {Hans Henrik} and Giuseppe Remuzzi and Toto, {Robert D.} and Vaziri, {Nosratola D.} and Christoph Wanner and Janet Wittes and Danielle Wrolstad and Chertow, {Glenn M.}",
year = "2013",
doi = "10.1056/NEJMoa1306033",
language = "English",
volume = "369",
pages = "2492--2503",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "26",

}

TY - JOUR

T1 - Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

AU - De Zeeuw, Dick

AU - Akizawa, Tadao

AU - Audhya, Paul

AU - Bakris, George L.

AU - Chin, Melanie

AU - Christ-Schmidt, Heidi

AU - Goldsberry, Angie

AU - Houser, Mark

AU - Krauth, Melissa

AU - Lambers Heerspink, Hiddo J.

AU - McMurray, John J.

AU - Meyer, Colin J.

AU - Parving, Hans Henrik

AU - Remuzzi, Giuseppe

AU - Toto, Robert D.

AU - Vaziri, Nosratola D.

AU - Wanner, Christoph

AU - Wittes, Janet

AU - Wrolstad, Danielle

AU - Chertow, Glenn M.

PY - 2013

Y1 - 2013

N2 - BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to

AB - BACKGROUND: Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown. METHODS: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to

UR - http://www.scopus.com/inward/record.url?scp=84890946148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890946148&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1306033

DO - 10.1056/NEJMoa1306033

M3 - Article

C2 - 24206459

AN - SCOPUS:84890946148

VL - 369

SP - 2492

EP - 2503

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 26

ER -